Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry doublepost...
I had expected the numbers by now. I would think a participant in the conference call would want some time to read the numbers?!
There are 3 new documents on Jiangbo's website, check these links:
No. 1, looks the same as no. 2
Don't think there is anything really new. I knew we have an audit-committee, but didn't know there was a Nominating and Corporate Governance Committee also.
Now bring me those numbers!
Herbieholt57: As far as I know Jiangbo generates all its revenue within the PRC.
If the chinese Yuan is going to get more farily valued, thus will be more expensive, then Jiangbo will be worth more US dollars. So that will be good for us, the shareholders.
I don't think it will make it easier for the company to transfer funds out of china, I don't even know if there is a problem on that matter?
I will throw in an oldie I posted a long time ago.
Some sidenotes:
I think I posted this thing somewhere early 2008.
Today's valuation of most companies doesn't go beyond a PE of 10, so we know that the picture above probably will not become reality soon. On the other hand, best guess is that the share-count will not grow as fast as I thought when making up the numbers.
Next week something is surely going to happen:
numbers on Q4 of fiscal year 2010
But, what's more important, outlook for fiscal year 2011. Let's hope they will make something special of it.
I guess the rumours on an acquisition of two other chinese companies is not true. Haven't been able to find anything new on those matters.
Later today the numbers of shares short will be published, let's see if something has changed.
Have a nice weekend everybody.
P.S. Maybe our train will start rolling again
In the Hongrui deal Jiangbo paid a part of the price for the acquisition in shares. I think it was about 600,000 shares. These shares where to be distributed from Jiangbo to the seller within one year after all the TCM's from Hongrui where transfered to Jiangbo. Read about that deal here
Maybe that happened in the last few weeks/months. Now the recipient is selling ? Could that be a reason for the selling pressure there is/has been?
Jiangbo, just hurry up with the numbers on Q4 and give us an excellent outlook for fiscal year 2011!
I think we saw the bottom yesterday, so I have bought a few extra shares 100 @ $7.97
How do you say: Johnson & Johnson in chinese?
@BigGreen: I agree with everything you say. I think you start having the opinion that the game is changing as you once said ?
Maybe it is time I stop thinking about an exit strategy and start buying some extra shares... maybe Jiangbo will even offer existing shareholders a discount!
Food for thought it all is. I know I'll be checking imeigu regularly!
Something else.
From that site this below is a copy / paste:
These two medicine enterprise's purchase quoted price about 200,000,000 Yuan, 100,000,000 Yuanjiang wave drugs manufacture will carry on the payment through the company innate fund, the surplus 100,000,000 Yuan through the fund payment which this time will collect, the entire transaction estimate will complete at the end of this year. Regarding this news, the above two medicine company has not responded.
So total purchase amount for the two companies will be 29.7 Million dollar, 14.85 Million will be raised through an extra offering of shares and the other 14.85 Million will be paid out of the $35 Million financing deal that was done a few years ago?
The two companies are Laiyang Yongkang Co. and Laiyang Co.?
In case you guys haven't tried it already, run this one through a translator: www.jiangbo.cn
I don't know if it is possible that Jiangbo is already selling shares to get their $14 million (at these prices that would mean approximately 1,750,000 shares). I would think they'd have to make a deal with investors or announce to the public that they will be selling extra shares. I don't think they can silently sell shares to raise capital. Maybe someone who understand these rules better, can shed a light on this for us...
I find it strange that they need to raise extra capital, they have a lot of cash already?! Or is all that cash destined for other things related to their recent acquired land purchase rights. I hope all will be explained during next conference call or press-release with their outlook for the next year.
Form the bio Wubo Cao:
"Wubo Cao? - CEO & President
Mr. Cao, Chief Executive Officer, President and Chairman of Jiangbo Pharmaceuticals, Inc, also served as General Manager of Laiyang Jiangbo since 2003 with more than 20 years working experiences in pharmaceutical industry. Previously, from 1998 until 2003, he was General Manager of combined entity: Laiyang Jiangbo Pharmacy Co. Ltd. and Laiyang Jiangbo Chinese and Western Pharmacy Co. Ltd. From 1988 to 1998, he was working in Laiyang Yongkang Pharmaceutical factory as Marketing Manager continually. Prior to this, from 1981 to 1988, Mr. Cao completed his military service in Chinese Army, during which he was the President of sales in Laiyang Yongkang Pharmaceutical Factory."
So Mr. Cao worked for one of the supposed merger/acuisiton companies. Interesting.
That is what is confusing also: the article speaks about a $35 Million financing. That makes me think that this is old news (2007/2008). Or have they just completed a new financing for again 35 Million dollar? Why haven't we read anything about that, I would think it is obligatory to bring out a PR to let investors know?
Dates, names and numbers are a little confusing. As well as confusing is the tranlation in whole. I really don't know what to think about it.
I haven't found these links myself, just take a look at the Yahoo message board. I think you all know where to find it.
I know one thing, I want to sell my shares for $40 each. I don't want to wait longer than 12-18 months. I guess time is running out...
As always, time will tell...
Supposedly this article talks about a merger or something of that kind concerning Jiangbo, is there anybody here that reads chinese and can help us translate properly?
Read the article here
If I translate it with google than I really can't understand what it all means.
Don't try to catch the falling knife
Absolutely in top 10 of days with high volume. Maybe we have built a new foundation? Now let's start a long lasting uptrend. It´s time my patience gets rewarded.
Wouldn't suprise me if they drive this thing down to $7.25 (50% retracement of this years high $14.50)
Let's keep our fingers crossed that earnings-release and outlook will turn the trend for good.
@Sunwin: We don't know if it is Pope selling their shares. Maybe it is Ardsley or Wellington. Maybe marketmakers are helping shorts getting covered (last known number there where still 60k shares short), maybe it is Wubo Cao selling some of his 4+ Million shares to drive the price down in order to keep Pope from excercising warrants? Who knows, I really don't have a clue.
Hi BigGreen101: is JGBO marginable already? Would be nice for US-investors because this would seem a great time to buy some extra shares?
(In my dutch account there is no such thing as margin afaik)
zinsen (German) = interest (English) = rente (Dutch)
In our case Pope / Jiangbo, the interest rate is 6%.
Hi sunwin, I see you are a little bit more optimistic than I am. Let's hope it will work out just as we "predict".
Good luck
I guess someone knows the numbers on Q4 are not going to be as good as we expected. Why else are shares being traded at $9?
Or is one of the holders excercising warrants and cashing out?
It has been quiet around here, and not without reason. Nothing new to tell. Waiting for the numbers on Q4.
In the meantime I am going to make some "predictions":
- net income Q4 approx. 10 million (about the same as Q4 of FY 2009)
- that makes total net income for FY 2010 approx. 32 million (well above their prediction!)
- Hongrui operational, will add 6-7 million in revenues to FY 2011
- outlook for FY 2011: two new TCM's will be out (Yuandu Hanbi and Bezoar Yijn), market accepts Felodipine very well, revenues $115 million, net income $33 million
- shareprice will climb from $9 to $ 14 by the end of 2010
We'll see what will be true and what will not...
as always time will tell.
Have a nice weekend everybody.
(My next post hast to be something special, it will be nr. 996 for me on this particular board)
That makes three of us...
That's strange at 9:30 today more than 15,000 shares where sold at $10.98. A few minutes later we are at $9.60 ?!
Jiangbo is now showing up in a top ten, so that will draw some attention.
Unfortunately it is the top ten of biggest percentage decliners.
Look here.
A slight pause ?! I call it a major setback, but oh well, it's Jiangbo, things can change within a day. So we'll see.
Still big volume. Guess the institutional holders are making their moves, maybe it's Pope excercising warrants and selling shares.
The number on shorts (per Aug. 13th) will be out later this day. It would be interesting to see the short number being published every day.
Strange trading session today? All this volume and such a sad end...
I like this steady way up.
If we add a few percent every week the shareprice will be much this time around next year:
52 weeks x 1% = 167% shareprice $ 16.7
52 weeks x 2% = 280% shareprice $ 28.0
52 weeks x 3% = 465% shareprice $ 46.5
My list in the previous post seems outdated already: Invesco is missing and they show up at this website as holders of some shares in Jiangbo.
I think it needs to be published within 10 weeks after the 4th quarter has ended, that would mean the second half of Sept. 2010
Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
LAIYANG, China, Aug. 16 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (Nasdaq: JGBO) (the "Company" or "Jiangbo"), today announced that the Company received approval from the Shandong Food and Drug Administration ("Shandong FDA") to start the sales of Felodipine sustained release ("SR") tablets.
After the Company received approval from the Chinese State Food and Drug Administration ("SFDA") to start producing Felodipine SR tablets in early June this year, Shandong FDA reviewed the Company's manufacturing equipment and capacity to produce Felodipine SR tablets, examined the final products from its pilot production and approved the sale of Felodipine SR tablets. Felodipine SR is a well recognized generic drug to treat hypertension and is listed in China's Basic Medical Insurance Catalog for medical coverage.
As the current market leader recently increased the selling price of its Felodipine SR tablets, many of its distributors have turned to Jiangbo and expressed their interest in building a cooperative relationship. Jiangbo has engaged ten major distributors to sell this product in a number of different regions throughout China and believes that its strong distribution network will enable it to expand its market share in Felodipine SR tablets, quickly.
"We are very excited to begin the commercial launch of Felodipine SR tablets, which we believe will be a key revenue and profit growth driver for us in the next few years. We estimate revenue potential for this drug to be between $8 million and $12 million in the first twelve months of launch with a projected gross margin of at least 70%," said Mr. Linxian Jin, CEO of Jiangbo. "We believe the addition of Felodipine SR tablets will enrich our product portfolio and will strengthen our competitive market position, while providing more cost effective new medicine to meet growing patient demand."
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website ( http://www.jiangbopharma.com ).
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to execute its strategic plan. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
For more information, please contact:
Jiangbo Pharmaceuticals, Inc.
Ms. Elsa Sung, CFO
Phone: +1-954-903-9378 x2
Email: elsasung@jiangbo.com
Web: http:// www.jiangbopharma.com
CCG Investor Relations
Mr. Crocker Coulson, President
Phone: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com
SOURCE Jiangbo Pharmaceuticals, Inc.
Not really new, but nice to read:
http://www.moneyshow.com/investing/articles.asp?aid=tptp081210-20476
Nice research, BigGreen! It encourages me to hold on to my lousy few shares if they are holding such larger numbers.
The word "Some" in my post is a link to a page that shows a list of 4 holders of stock: Pope, Arcadian, Rochdale, Punch. You can see there that Arcadian and Punch have bought shares between 30th March and 30th of June. Together these four holders own 312,389 shares.
Hi all, back from vacation, thought I'd share some good news.
Some institutions are buying, that's nice.
Je suis en vacance en Francais , mais je vue que rien est changer pour JGBO. Bonne chance a tout et a bientot!
Just to put things into perspective: I bought 700 shares at $4.25 - $3.39 - $ 3.75 - $ 3.70. But unfortunately I bought far more shares at much higher levels, up to $16.40 way back in 2007.
When I add all up I am far below zero with todays shareprice. We need to go up for good! We've been bouncing back and forth, it is time we finally make a good rally and stay well above $10 and start a steady climb to 20 or 30 in the next 2-3 years (wishfull thinking).
In a bad case scenario we'll stay around these levels untill the whole deal wth Pope has been handled. That means at least until May 2011 (debenture matures) or even May 2013 (warrants expire).
I dont'want to think about worst case, because I still honestly think fundamentals are good.
As always, time will tell.